Study wrapper · #878
Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
Editor's note
A small prospective cohort (n=28) tracking body composition and diet during semaglutide or tirzepatide therapy, notable for flagging estimated muscle-mass loss and unchanged diet quality. The sample is tiny with attrition, muscle mass was estimated by bioimpedance, and the authors themselves label the findings exploratory. Still a useful, honest signal on the nutrition and lean-mass gaps that can accompany pharmacologic weight loss.
Plain-language abstract
In a small 24-week study of adults on semaglutide or tirzepatide without structured nutrition support, participants lost substantial weight and fat but also lost estimated muscle mass, and their diet quality and food cravings did not improve overall. Higher protein intake was associated with better muscle preservation.